Business ❯ Healthcare ❯ Biotechnology

Pharmaceuticals

ImmunityBio, Inc. Vaccine Development Monoclonal Antibodies Clinical Trials Rare Diseases Cancer Treatment Atara Biotherapeutics Cystic Fibrosis Treatments Gene Therapy Biologic Products

Legend Biotech Reports First Profitable Quarter as CARVYKTI Sales Surge

Stronger sales have built a near‑$1 billion cash reserve to fund global access growth plus a planned U.S. IND for a next‑generation CAR‑T.

Artisan Small Cap Fund Posts Strong Q2 Gain and Rebalances Toward AI Infrastructure and Health Care

Investors Vie to Lead ImmunityBio Securities Suit

NervGen Prices $60 Million Public Offering of Shares and Warrants

Boxer Capital Buys 1.24 Million Vir Biotechnology Shares

ImmunityBio Investors Face May 26 Lead-Plaintiff Deadline in Securities Suit Tied to FDA Anktiva Rebuke

ImmunityBio Investors Face May 26 Deadline in Securities Class Action Over FDA Ad Rebuke

ImmunityBio Securities Fight Intensifies After FDA Rebuke Over Anktiva Claims

Axsome Reports 57% Q1 Sales Jump as FDA Clears Auvelity for Alzheimer’s Agitation

Class Action Filed Against Atara Biotherapeutics Over Alleged Misstatements on FDA Setbacks

ImmunityBio Investors Face May 26 Deadline in Class Action After FDA Flags Misleading Anktiva Claims

ImmunityBio Faces Investor Suits After FDA Rebuke as Anktiva Sales Jump

Investor Class Actions Target Atara Over FDA Setbacks to EBVALLO

ADMA Biologics Denies Short-Seller Report as Shares Rebound and Law Firms Launch Probes

Summit Therapeutics Shares Rally as Ivonescimab Trials Near Q2 Readout

Kynam Trims Syndax Stake With $8.18 Million Q4 Sale Disclosed in SEC Filing

ClearBridge Growth Strategy Posts Third Straight Outperformance in Q4 2025

Kite Pharma to Buy Interius for $350 Million, Adding In‑Vivo CAR‑T Platform

Biontech Reports Q1 Loss as Focus Shifts to mRNA Cancer Therapies

Biogen Reports Mixed Q4 Results and Lowers 2025 Outlook